Clinical Trials
8 trialsNCT04042051 2025-07-22
Panthera
Cancer Trials Ireland
Phase 1 Terminated
NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT04431635 2024-09-27
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT04933617 2024-07-09
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04156828 2023-06-29
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
University of Washington
Phase 1 Terminated
NCT03128619 2022-09-26
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT03886649 2022-04-01
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Swiss Cancer Institute
Phase 1 Terminated